No article notes available at this time.
• ASPS has no established effective systemic treatment, and this trial provides some of the strongest prospective evidence for a targeted agent in this rare, chemoresistant sarcoma. • A 35% ORR with 84% disease control at 24 weeks demonstrates meaningful single-agent VEGFR-inhibitor activity, giving residents a benchmark for what response looks like in ASPS trials. • These results prompted a randomized phase II trial comparing cediranib with sunitinib, so this study is a key reference point for understanding the current evidence trajectory for ASPS systemic therapy.
No article notes available at this time.
• ASPS has no established effective systemic treatment, and this trial provides some of the strongest prospective evidence for a targeted agent in this rare, chemoresistant sarcoma. • A 35% ORR with 84% disease control at 24 weeks demonstrates meaningful single-agent VEGFR-inhibitor activity, giving residents a benchmark for what response looks like in ASPS trials. • These results prompted a randomized phase II trial comparing cediranib with sunitinib, so this study is a key reference point for understanding the current evidence trajectory for ASPS systemic therapy.